Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease

Benzinga_recent_news12-12

On Wednesday, Roche Holdings AG (OTC:RHHBY) shared data from the phase 3 lidERA Breast Cancer study. The study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590154331?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Roche-Logo--Signage-On-The-Facade-Of-Roc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-12 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590154331","market":"hk","top_or_hot":-1,"title":"Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease","media":"Benzinga_recent_news","content":"<div>\n<p>On Wednesday, Roche Holdings AG (OTC:RHHBY) shared data from the phase 3 lidERA Breast Cancer study.\nThe study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-12 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, Roche Holdings AG (OTC:RHHBY) shared data from the phase 3 lidERA Breast Cancer study.\nThe study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OS","symbol_name":"OneStream, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease","article_id":"2590154331","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Roche-Logo--Signage-On-The-Facade-Of-Roc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49341601/roches-oral-breast-cancer-drug-shows-30-drop-in-recurrence-in-patients-with-early-disease","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590154331","pubTimestamp":1765474020,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive breast cancer with a consistent safety profile.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OS":"OneStream, Inc.","BK4585":"ETF&股票定投概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","NVS":"诺华","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4578":"CAR-T","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4007":"制药","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4097":"系统软件","BK4532":"文艺复兴科技持仓"},"translate_title":"罗氏口服乳腺癌药物显示早期疾病患者复发率下降30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OS":1,"NVS":1},"content_text":"On Wednesday, Roche Holdings AG (OTC:RHHBY) shared data from the phase 3 lidERA Breast Cancer study.\nThe study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer.\nThe lidERA results were presented at the 2025 San Antonio Breast Cancer Symposium.\nRoche, in a press release on Wednesday, said Giredestrant is the first and only oral selective oestrogen receptor degrader (SERD) to show superior iDFS in the adjuvant setting, and lidERA is the second positive phase 3 readout for giredestrant following the evERA Breast Cancer results in the metastatic setting.\nAlso Read: Roche Targets Top Spot In Weight Loss Drug Market\nAt the pre-specified interim analysis, adjuvant giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% (invasive disease-free survival [iDFS]) compared with standard-of-care endocrine therapy (SoC ET).\nAt three years, 92.4% of patients in the giredestrant arm were alive and free of invasive disease versus 89.6% in the SoC ET arm. The iDFS benefit was consistent across all clinically relevant subgroups.\nOverall survival (OS) data were immature at the time of this analysis, but a clear positive trend was observed.\nFollow-up for OS will continue to the next analysis.\nGiredestrant also demonstrated a 31% risk reduction of distant recurrence-free interval– another key secondary endpoint.\nGiredestrant was well tolerated, and adverse events were manageable and consistent with its known safety profile.\nReuters noted that the results suggest giredestrant could become a new standard in adjuvant endocrine therapy, though it remains unclear which patients might still require add-on CDK4/6 inhibitors such as Novartis AG's (NYSE:NVS) Kisqali.\nRoche Chief Medical Officer Levi Garraway told Reuters that a 30% improvement in disease-free survival means patients are 30% less likely to experience a recurrence compared with standard care.\nJPMorgan analysts previously estimated the adjuvant indication could generate about $5 billion in annual revenue if approved.\nRead Next:\nPhoto by OleksSH via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590154331","isCrawlerRequest":true}